Core Insights - Silo Pharma, Inc. has selected Allucent to assist in the final preparations for its investigational new drug application (IND) for the Phase 1 clinical trial of its intranasal prophylactic SPC-15 aimed at treating PTSD, with plans to submit the IND in 2026 [1][2] - The partnership with Allucent is viewed as a significant advancement in bringing the PTSD therapeutic to clinical trials, leveraging Allucent's expertise to ensure a robust IND submission [2] - Silo Pharma's therapeutic focus includes addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 for PTSD and other programs targeting fibromyalgia and Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on innovative programs for various medical conditions [3] - The company collaborates with leading universities and laboratories to conduct its research [3] Allucent Overview - Allucent is a global full-service clinical research organization with over 30 years of experience, providing comprehensive drug development solutions across various therapeutic areas [4] - The organization aims to assist biopharma and government clients in overcoming challenges in bringing new therapies to market [4]

Drug Development and Research - The company is developing novel therapeutics targeting PTSD, stress-induced anxiety disorders, fibromyalgia, and CNS diseases, with a lead program, SPC-15, focusing on PTSD and anxiety [180]. - SPC-15 is designed as an intranasal drug and is expected to qualify for the FDA's streamlined 505(b)(2) regulatory pathway, with a pre-IND submission planned for 2026 [189][191]. - SP-26, a ketamine-based implant for fibromyalgia, is in preclinical research, with initial animal studies evaluating dosage and time release [193][195]. - The global Alzheimer's therapeutics market is projected to exceed $30.8 billion by 2033, presenting a significant opportunity for SPC-14, which targets cognitive symptoms in Alzheimer's disease [196]. - The company has entered into a license agreement with the University of Maryland for a ketamine polymer implant and a sponsored research agreement with Columbia University for Alzheimer's treatment [185][196]. - SPU-16 targets CNS disorders, with an initial indication for multiple sclerosis, and has been granted an exclusive option for a new commercial license [198][202]. - The company is actively pursuing the acquisition and development of intellectual property to treat rare diseases, expanding its business focus [186]. Financial Performance - Revenues for the three months ended September 30, 2025, and 2024 were both $18,025, while for the nine months, revenues remained at $54,076 for both years [210]. - Cost of revenues for the three months ended September 30, 2025, was $20,687, a significant increase from $1,459 in 2024; for the nine months, it rose to $23,606 from $4,378 [211]. - Total operating expenses for the three months ended September 30, 2025, were $1,148,804, up from $1,026,621 in 2024, and for the nine months, they increased to $3,524,608 from $2,942,040 [212]. - Research and development expenses for the three months ended September 30, 2025, were $543,615, a 5.0% increase from $517,548 in 2024; for the nine months, expenses surged to $1,854,824 from $1,292,437, marking a 43.5% increase [216]. - Loss from operations for the three months ended September 30, 2025, was $1,151,466, compared to $1,010,055 in 2024, reflecting a 14.0% increase; for the nine months, the loss increased to $3,494,138 from $2,892,342, a 20.8% rise [223]. - Net loss for the three months ended September 30, 2025, was $1,110,438, or $0.12 per share, compared to a net loss of $928,814, or $0.22 per share, in 2024, an increase of 19.6%; for the nine months, net loss was $3,346,168, or $0.50 per share, up from $2,662,260, or $0.78 per share, a 25.7% increase [226]. Cash Flow and Investments - As of September 30, 2025, working capital was $5,456,030, with $1,948,579 in short-term investments and $3,917,627 in cash and cash equivalents, compared to $5,455,483 in working capital at the end of 2024 [228]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $3,881,061, an increase of 33.1% from $2,916,482 in 2024 [232]. - Net cash provided by investing activities for the nine months ended September 30, 2025, was $1,164,009, a 15.1% increase from $1,011,436 in 2024 [233]. - On September 29, 2025, the company received net proceeds of $2,146,000 from the October 2025 Offering, which helps mitigate concerns about its ability to continue as a going concern [237]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $3,346,168, reflecting a net loss adjusted for non-cash items and changes in operating assets and liabilities [238]. - Net cash provided by investing activities for the nine months ended September 30, 2025, was $1,164,009, consisting of proceeds from the sale of short-term investments of $1,315,653 [238]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $2,728,880, which included net proceeds from the sale of common stock and pre-funded warrants of $1,593,897 [238]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $2,662,260, adjusted for non-cash items and changes in operating assets and liabilities [238]. - Net cash provided by investing activities for the nine months ended September 30, 2024, was $1,001,436, with proceeds from the sale of short-term investments of $1,149,320 [238]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was $3,241,628, including net proceeds from the sale of common stock and pre-funded warrants of $1,673,216 [238]. Accounting and Compliance - Stock-based compensation is recognized based on the grant-date fair value of the award, in accordance with ASC 718 [241]. - Research and development costs are expensed when incurred, with significant estimates related to the percentage of completion of certain projects [242]. - The company does not expect the adoption of new accounting guidance to have a material impact on its consolidated financial statements [243]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [245]. Digital Assets and Treasury Management - The company holds approximately $400,000 in digital assets as part of its cryptocurrency treasury strategy initiated in August 2025 [204]. - The gross proceeds from the October 2025 Offering were $2,500,000, with net proceeds of $2,146,000 after deducting fees and expenses [207]. - The company has engaged Fireblocks for its institutional crypto treasury platform, enhancing its digital asset management capabilities [206].

Core Insights - Silo Pharma has selected the Alphaledger/Simplify Target 12% Distribution Fund as a key part of its real-world asset investment strategy, aiming to diversify its treasury and integrate digital assets [1][3] - The Alphaledger T12 Fund is designed to provide high monthly income through a diversified portfolio of alternative income-generating strategies, operating on the Solana blockchain for efficiency and low costs [2][3] - The investment reflects a broader trend among institutions to incorporate tokenized real-world assets into their balance sheets, enhancing transparency and compliance in financial products [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders and chronic pain [7] - The company is engaged in innovative therapeutic programs, including SPC-15 for PTSD and SP-26 for fibromyalgia, and collaborates with leading universities for research [7] Fund Overview - The Alphaledger T12 Fund is a digital-native investment vehicle that provides access to tokenized real-world assets, leveraging blockchain technology for efficient investment pathways [2][4] - Managed by Alphaledger Investment Management LLC, the fund aims to transform investing through blockchain-powered asset tokenization [5][6]

Core Insights - Silo Pharma is preparing to submit an investigational new drug (IND) application for its lead candidate SPC-15, aimed at treating PTSD and stress-induced anxiety, with preparations expected to commence before year-end 2025 [1][2][8] - The company has launched a digital assets treasury strategy to enhance capital resources and participate in cryptocurrency growth, combining staking for yield with a hedged overlay to mitigate volatility [2][4] Biopharmaceutical Platform - SPC-15 is advancing through final preparations for the IND submission, with positive results from a large animal safety study supporting its formulation [4][5] - The company is finalizing a drug-device study for the microchip-based nasal spray system used in SPC-15 delivery and has completed a GLP-compliant toxicology study, with data expected in early 2026 [5][8] - Silo is expanding its global intellectual property portfolio for SPC-15 technology, securing patents in the U.S., Australia, and Japan [5] Digital Assets Treasury - Initial cryptocurrency purchases have been made in Bitcoin, Ethereum, Solana, and ResearchCoin, with a focus on multi-chain digital asset growth and DeFi integration [5][6] - A new Crypto Advisory Board has been formed to enhance support for cryptocurrency audit and compliance, with additional members expected to join soon [5][6] - The company has engaged Fireblocks for secure institutional-grade infrastructure and custody technology services for its crypto treasury platform [5][6] Future Outlook - Significant milestones are anticipated in both drug development and digital asset purchases, positioning Silo to capitalize on emerging opportunities [6] - The company plans to pursue additional therapeutic indications for SPC-15 and secure the FDA's 505(b)(2) accelerated regulatory pathway for clinical development [8]

Core Insights - Silo Pharma has initiated its first Bitcoin purchase as part of a broader crypto reserve strategy aimed at multi-chain asset growth [1][2] - The CEO of Silo Pharma expressed confidence in Bitcoin as a store of value and a hedge against market volatility, highlighting the company's commitment to digital asset investments [2] - Silo Pharma's portfolio includes various therapeutic programs targeting conditions such as PTSD, fibromyalgia, and CNS diseases, developed in collaboration with leading universities [3] Company Overview - Silo Pharma operates as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [3] - The company focuses on addressing underserved medical conditions, including stress-induced psychiatric disorders and chronic pain [3] - Silo's innovative programs include SPC-15 for PTSD and SP-26 for fibromyalgia, along with preclinical assets for Alzheimer's disease and multiple sclerosis [3]

Core Insights - Silo Pharma has initiated its first Bitcoin purchase as part of a broader crypto reserve strategy aimed at multi-chain asset growth [1][2] - The CEO of Silo Pharma expressed confidence in Bitcoin as a store of value and a hedge against market volatility, highlighting the company's commitment to digital asset investments [2] - Silo Pharma's portfolio includes various therapeutic programs targeting conditions such as PTSD, fibromyalgia, and CNS diseases, indicating a diversified focus beyond cryptocurrency [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on underserved medical conditions [3] - The company collaborates with leading universities and laboratories for its research initiatives [3] Investment Strategy - The company has made multiple crypto investments, including Ethereum, RSC, and Solano tokens, and plans to continue expanding its digital asset portfolio [2] - The strategic approach reflects the company's belief in the growing adoption and value creation opportunities within the cryptocurrency market [2]

Company Overview - Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4] - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis, developed in collaboration with leading universities and laboratories [4] Investment in DeSci - Silo Pharma has made an initial purchase of ResearchCoin (RSC), the native token of ResearchHub, as part of its strategy to expand its digital assets treasury and capture long-term value from emerging multi-chain opportunities [1][2] - The investment in RSC aligns with the growing decentralized science (DeSci) movement, which emphasizes the use of blockchain technologies and token-based economics to modernize scientific research and collaboration [2] DeSci Movement - DeSci represents a transformative growth opportunity in the scientific research sector, with the potential to unlock a trillion-dollar global research economy currently tied up in grants, universities, and pharmaceutical pipelines [3] - By tokenizing research funding and intellectual property, DeSci can create profit opportunities years before traditional biotech exits, allowing investors to capture upside earlier and access new growth avenues in the biotech sector [3]

Core Points - Silo Pharma, Inc. has completed a registered direct offering of 2,857,143 shares of common stock at a price of $0.875 per share, raising approximately $2.5 million in gross proceeds [1][2] - In addition to the stock offering, the company issued unregistered warrants for the purchase of an equal number of shares at an exercise price of $0.75, which are immediately exercisable and will expire in five years [1][2] - The proceeds from the offering will be used for working capital and general corporate purposes [2] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1] - The company targets underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with programs including SPC-15 for PTSD and SP-26 for fibromyalgia [6] - Silo Pharma conducts research in collaboration with leading universities and laboratories [6]

Core Viewpoint - Silo Pharma, Inc. has announced a registered direct offering of 2,857,143 shares of common stock at a price of $0.875 per share, along with a concurrent private placement of unregistered warrants to purchase an equal number of shares at an exercise price of $0.75 per share [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $2.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about October 1, 2025, subject to customary closing conditions [1]. - The unregistered warrants will be immediately exercisable upon issuance and will expire five years from the effective date of the registration statement [1]. Group 2: Regulatory Information - The common stock is being offered under a "shelf" registration statement that was declared effective by the SEC on January 30, 2024 [3]. - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under the Securities Act or applicable state laws [4]. Group 3: Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1]. - The company addresses underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases, with programs targeting PTSD, fibromyalgia, Alzheimer's disease, and multiple sclerosis [6].

Core Insights - Silo Pharma has initiated a strategic agreement with Fireblocks to enhance its crypto treasury management platform, leveraging Fireblocks' expertise in secure digital asset custody and management [1][2]. Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [3]. - The company's therapeutic portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [3]. Partnership Details - Fireblocks is recognized as a leader in the digital assets space, having facilitated the secure transfer of over $10 trillion to date, and offers a multi-layer security framework that includes multi-party computation technology and a deposit address authentication network [2]. - The collaboration aims to build an institutional-grade infrastructure that enables Silo to buy, stake, and manage digital assets at scale [2].